DASH
Repository logo
Communities & Collections
Browse DASH
DASH Stories
Statistics
  1. Home
  2. Harvard Division of Continuing Education
  3. DCE Theses and Dissertations
  4. Genetic Variation in the BRCA2 Gene and Prostate Cancer Risk in the Health Professionals Follow-Up Study (HPFS) and Physicians' Health Study (PHS)

Genetic Variation in the BRCA2 Gene and Prostate Cancer Risk in the Health Professionals Follow-Up Study (HPFS) and Physicians' Health Study (PHS)

Open/View files
LEGGE-DOCUMENT-2016.pdf (642.66 KB)
Date
March 22, 2016
Author(s)
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Legge, Sarah A. 2016. Genetic Variation in the BRCA2 Gene and Prostate Cancer Risk in the Health Professionals Follow-Up Study (HPFS) and Physicians' Health Study (PHS). Master's thesis, Harvard Extension School.
Abstract
There is an urgent need to identify biomarkers that may be linked to aggressive and early-onset forms of prostate cancer. Previous studies have identified a link between mutations in the BRCA2 tumor suppressor gene and prostate cancer. The primary goal of this study was to assess the role of genetic variation in the BRCA2 gene on the risk of prostate cancer, both overall risk and risk of more advanced or aggressive disease. This study utilized genotype data from nested case-control studies as part of the Health Professionals Follow-up Study (HPFS) and the Physicians’ Health Study (PHS), and identified 136 single nucleotide polymorphisms (SNPs) in the BRCA2 gene. We calculated per-allele odds ratios (ORs) and 95% confidence intervals (95% CIs) using unconditional logistic regression, adjusted for the matching factors for each of the SNPs. This study failed to identify SNPs within the BRCA2 gene that were statistically significantly associated with risk of prostate cancer. We observed no strong association across all cohorts between genetic variation in BRCA2 and risk of prostate cancer. One SNP, rs10492396, was found to be associated with an increased risk of prostate cancer, only in the HPFS. None of the SNPs were associated with risk of fatal prostate cancer. Further studies are needed to understand the potential role of variation in the tumor suppressor gene BRCA2 and prostate cancer risk.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
URI
http://nrs.harvard.edu/urn-3:HUL.InstRepos:33797297
Subjects

Biology, Biostatistic...

Collection
DCE Theses and Dissertations
Metrics
Repository logo
  • CONTACT US
  • OSRDS
  • ABOUT DASH
  • DEPOSITING TO DASH
  • TERMS OF USE
  • REQUEST A WAIVER
  • TAKE DOWN POLICY
  • NAME CHANGE POLICY
  • HARVARD OA POLICIES
  • DASH SUBMITTER AGREEMENT
  • Accessibility
  • Privacy
Creative Commons License BY
Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License,
which allows anyone to share and adapt our material as long as proper attribution is given.
For details and exceptions, see the Harvard Library Copyright Policy
©2024 Presidents and Fellows of Harvard College.